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Advisory Committee on Immunization Practices Recommended 
Immunization Schedule for Children and Adolescents  
Aged 18 Years or Younger — United States, 2019
Candice L. Robinson, MD1; Henry Bernstein, MD2; José R. Romero, MD3,4; Peter Szilagyi, MD5
At its October 2018 meeting, the Advisory Committee on 
Immunization Practices (ACIP)* voted to recommend approval 
of the Recommended Immunization Schedule for Children 
and Adolescents Aged 18 Years or Younger, United States, 
2019. The 2019 child and adolescent immunization schedule 
summarizes ACIP recommendations, including several changes 
from the 2018 immunization schedule,† on the cover page, 
three tables, and notes found on the CDC immunization 
schedule website (https://www.cdc.gov/vaccines/schedules/
index.html). This immunization schedule is recommended 
by ACIP and approved by the CDC Director, the American 
Academy of Pediatrics, the American Academy of Family 
Physicians, and the American College of Obstetricians and 
Gynecologists. Health care providers are advised to use the 
tables and the notes together.
ACIP’s recommendations on use of each vaccine are devel-
oped after in-depth reviews of vaccine-related data, including 
disease epidemiology and burden, vaccine efficacy and effec-
tiveness, vaccine safety, quality of evidence, feasibility of pro-
gram implementation, and economic analyses of immunization 
policy (1). The child and adolescent immunization schedule 
is published annually to consolidate and summarize updates 
to ACIP recommendations on vaccination of children and 
adolescents and to assist health care providers in implementing 
current ACIP recommendations. The use of trade names of 
vaccines in this report and in the child and adolescent immu-
nization schedule is for identification purposes only and does 
not imply endorsement by ACIP or CDC.
For further guidance on the use of each vaccine, including 
contraindications and precautions, health care providers are 
referred to the respective ACIP vaccine recommendations 
* Recommendations for routine use of vaccines in children and adolescents are 
developed by ACIP, a federal advisory committee chartered to provide expert 
external advice and guidance to the CDC Director on use of vaccines and related 
agents for the control of vaccine-preventable diseases in the civilian population 
of the United States. Recommendations for routine use of vaccines in children 
and adolescents are harmonized to the greatest extent possible with 
recommendations made by the American Academy of Pediatrics, the American 
Academy of Family Physicians, and the American College of Obstetricians and 
Gynecologists. ACIP recommendations approved by the CDC Director become 
agency guidelines on the date published in the Morbidity and Mortality Weekly 
Report. Additional information about ACIP is available at https://www.cdc.gov/
vaccines/acip.
† Past immunization schedules are available at https://www.cdc.gov/vaccines/
schedules/past.html.
§ CDC encourages organizations to use syndication as a more reliable method 
for displaying the most current and accurate immunization schedules on an 
organization’s website rather than copying these schedules to their websites. 
Use of content syndication requires a one-time step that ensures an organization’s 
website displays current schedules as soon as they are published or revised; 
instructions for the syndication code are available on CDC’s website (https://
www.cdc.gov/vaccines/schedules/syndicate.html). CDC also offers technical 
assistance for implementing this form of content syndication (e-mail request 
to ncirdwebteam@cdc.gov). Changes in ACIP recommendations in the child 
and adolescent immunization schedule before the next scheduled annual update, 
if any, are available at https://www.cdc.gov/vaccines/schedules/hcp/child-
adolescent.html.
at https://www.cdc.gov/vaccines/hcp/acip-recs/index.html. 
Changes in recommended use of vaccines can occur between 
annual updates to the child and adolescent immunization 
schedule. These changes, if made, are available at https://www.
cdc.gov/vaccines/acip/recommendations.html).§ Printable ver-
sions of the 2019 child and adolescent immunization schedule 
and ordering instructions are available on the immunization 
schedule website.
Vaccine Changes in the 2019 Immunization 
Schedule for Children and Adolescents
Vaccine changes in the 2019 immunization schedule for 
children and adolescents aged ≤18 years include new or revised 
ACIP recommendations for hepatitis A vaccine (HepA) (2), 
hepatitis B vaccine (Hep B) (3), influenza vaccine (4), and teta-
nus toxoid, reduced diphtheria toxoid, and acellular pertussis 
vaccine (Tdap) (5), as well as clarification of the recommenda-
tions for inactivated poliovirus vaccines (IPV).
Changes Affecting Multiple Portions of the 
Schedule
The overall appearance of the 2019 child and adolescent 
schedule has been updated because of recommendations result-
ing from a recent evaluation of the child and adolescent immu-
nization schedule. An internet survey of 249 pediatricians 
and family medicine physicians was conducted to assess their 
familiarity with the schedule, the environment in which the 
schedule is used, the frequency and circumstances of use, and 
their impressions and preferences on redesigned drafts of the 
child and adolescent immunization schedule. These changes 
have been applied to all portions of the immunization sched-
ule, including the cover page, routine immunization schedule 
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(Table 1), catch-up schedule (Table 2), medical indications for 
each vaccine (Table 3), and notes with details for each vaccine.
Cover Page. Changes to the cover page are as follows:
• Guidance on how to use the schedule was added to the 
top of the document.
• Live attenuated influenza vaccine (LAIV) was added to 
the vaccine table.
• A Helpful Information section, which includes links to the 
ACIP recommendations, the General Best Practice Guidelines 
for Immunization, and the Manual for the Surveillance of 
Vaccine-Preventable Diseases, has been added.
Table 1. Changes to Table 1 (previously known as Figure 1) 
are as follows:
• A separate row has been added for LAIV.
• A purple bar has been added to the Hepatitis A (HepA) 
row at age 6–11 months to represent use in infant travelers.
• Within the Tetanus, diphtheria, & acellular pertussis 
(Tdap: ≥7 yrs) row, the bar for persons aged 13–18 years 
has been split into a half green and half purple bar to 
represent catch-up vaccination and use in pregnant 
adolescents, respectively.
Table 2. Changes to Table 2 (previously known as Figure 2) 
are as follows:
• Minor changes to the order in which guidance is presented 
in the Haemophilius influenzae type b and Pneumococcal 
conjugate rows were made. The criteria under which no 
further doses are needed are now presented first, followed 
by recommendation for those for whom additional doses 
are indicated.
Table 3. Changes to Table 3 (previously known as Figure 3) 
are as follows:
• A new pink color has been added to the legend, which 
represents “Delay vaccination until after pregnancy if 
vaccine indicated.” This color is used in the pregnancy 
column for human papillomavirus vaccine.
• The Contraindicated and Precaution for vaccination boxes 
in the legend have been defined with narrative text.
• A row for LAIV has been added.
• The Pregnancy cell in the meningococcal B vaccine row has 
been changed to the orange Precaution for vaccination color.
Notes. The notes (previously known as footnotes) are 
presented in alphabetical order rather than linked by numeri-
cal superscripts as in previous years. Edits have been made 
throughout the Notes section to harmonize language between 
the child and adolescent schedule and the adult immunization 
schedule, where possible. In addition, the following content 
changes were made:
• The HepA note was revised to include information 
regarding the use of combined HepA-HepB vaccine in 
persons aged ≥18 years. A section for international travel 
has been added with recommendations for vaccination of 
travelers aged 6–11 months and unvaccinated travelers 
aged ≥12 months. Homelessness also has been added as 
an indication for HepA vaccination.
• The HepB note was revised to include information regarding 
the use of CpG-adjuvanted HepB vaccine and combination 
HepA-HepB vaccine in persons aged ≥18 years.
• Within the IPV note, a bullet has been added regarding 
the use of combination vaccines that contain IPV.
• The Influenza vaccines note has been updated to indicate 
that LAIV can be used during the 2018–19 influenza 
season. A Special Situations section has been added with 
information regarding vaccination of persons with a 
history of egg allergy and circumstances under which LAIV 
use is not recommended.
• During mumps and meningococcal disease outbreaks, the 
Additional Information section at the beginning of the 
notes directs providers to their state or local health 
department for information regarding vaccination during 
an outbreak. Therefore, language regarding the use of 
measles, mumps, and rubella (MMR) vaccine in the setting 
of a mumps outbreak or the use of meningococcal (groups 
A, C, W-135, and Y) conjugate (MenACWY) and 
meningococcal group B (MenB) vaccines in the setting of 
meningococcal disease outbreaks has been removed from 
the MMR and meningococcal vaccine notes.
• The Tdap note has been updated to indicate that those 
persons who received a dose of Tdap or diphtheria and 
tetanus toxoids and acellular pertussis vaccine (DTaP) at 
age 7–10 years inadvertently or as part of the catch-up 
series should still receive the routine dose of Tdap at age 
11–12 years. A link to information regarding use of Tdap/
tetanus and diphtheria toxoids (Td) for wound prophylaxis 
also has been added.
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